RUNX1 and acute myeloid leukemia: Genetic abnormalities, including chromosomal abnormalities and mutations in proliferation/survival mechanisms (FLT3) and differentiation/apoptosis pathways (CEBPA, RUNX1, and NPM1), play a pathogenetic role in AML, provide prognostic criteria, and can guide therapy (3–5).